Why could patients with HF and T2DM benefit from SGLT2i?10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma, MD, PhD, St Michael’s Hospital, Toronto, ON, Canada
This lecture by Prof. Verma was part of a CME accredited symposium: Heart Failure, diabetes & SGLT2i: Time to change practice? held at ESC Heart Failure 2019 in Athens, Greece.
Prof. Subodh Verma, MD, PhD is an internationally renowned cardiac surgeon‐scientist at St Michael’s Hospital in Toronto and Professor at the University of Toronto. He is a trained pharmacist with a PhD in cardiovascular pharmacology from the University of British Columbia. Dr. Verma has published over 200 peer‐reviewed papers and more than 400 abstracts, with several papers appearing in the New England Journal of Medicine, Nature, Circulation and Circulation Research. He oversees an active research team that focuses on the role of risk factors and inflammation on endothelial function, vascular homeostasis and cardiac function.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.